The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): A novel histopathological finding requiring the application of lineage specific markers

Journal of Clinical Pathology

Volumn 59, Issue 3, 2006, Pages 298-302

  Horny, H P ^a,b   Sotlar, K ^c   Stellmacher, F ^b   Krokowski, M ^b   Agis, H ^d   Schwartz, L B ^e   Valent, P ^d  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2D7 ANTIGEN; ANTIGEN; CD34 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; STEM CELL FACTOR RECEPTOR; TRYPTASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BASOPHIL; BONE MARROW BIOPSY; CELL INFILTRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC SYSTEM TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MAST CELL; MAST CELL LEUKEMIA; MYELOMASTOCYTIC LEUKEMIA; POINT MUTATION; PRIORITY JOURNAL; SYSTEMIC MASTOCYTOSIS; TRYPTASE POSITIVE COMPACT ROUND CELL INFILTRATE OF THE BONE MARROW;

ADULT; AGED; AGED, 80 AND OVER; BASOPHILS; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELL LINEAGE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA, MAST-CELL; MALE; MAST CELLS; MASTOCYTOSIS; MIDDLE AGED; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, INTERLEUKIN-2; RETROSPECTIVE STUDIES; SERINE ENDOPEPTIDASES; TRYPTASES;

EID: 33644763309     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.028738     Document Type: Article

References (31)

1. Horny H-P, Sillaber C, Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998;22:1132-40.
2. Li CY. Diagnosis of mastocytosis: value of cytochemistry and immunohistochemistry. Leuk Res 2001;25:537-41.
3. Li WV, Kapadia SB, Sonmez-Alpan E, Swerdlow SH. Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies. Mod Pathol 1996;9:982-8.
4. Horny H-P, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001;25:543-51.
5. Horny H-P, Valent P. Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol 2002;127:115-17.
6. Valent P, Horny H-P, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-25.
7. Valent P, Horny H-P, Li CY, et al. Mastocytosis (Mast cell disease). In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Tumours of haematopoietic and lymphoid tissues 2001:291-302.
8. Fukuda T, Kamishima T, Tsuura Y, et al. Expression of the c-kit gene product in normal and neoplastic mast cells but not in neoplastic basophil/mast cell precursors from chronic myelogenous leukaemia. J Pathol 1995;177:139-46.
9. Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol 2001;32:545-52.
10. Kepley CL, Craig SS, Schwartz LB. Identification and partial characterization of a unique marker for human basophils. J Immunol 1995;154:6548-55.
11. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.
12. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.
13. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization (WHO) classification of tumours. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues, 2001;1, 291-302.
14. Sperr WR, Horny H-P, Lechner K, et al. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma 2000;37:473-86.
15. Valent P, Samorapoompichit P, Sperr WR, et al. Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematol J 2002;3:90-4.
16. Valent P, Spanblöchl E, Bankl HC, et al. Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemic blast crisis. Blood 1994;84:4322-32.
17. Sperr WR, Hauswirth AW, Valent P. Tryptase a novel biochemical marker of acute myeloid leukemia. Leuk Lymphoma 2002;43:2257-61.
18. Sperr WR, Jordan JH, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001;98:2200-9.
19. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
20. Sotlar K, Fridrich C, Mall A, et al. Detection of c-kit point mutation Asp-816→Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res 2002;26:979-84.
21. Sotlar K, Horny H-P, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004;28:1319-25.
22. Samorapoompichit P, Kiener HP, Schernthaner GH, et al. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood 2001;98:2580-3.
23. Horny H-P, Parwaresch MR, Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol 1985;16:808-14.
24. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991;96:2-4S.
25. Parwaresch MR, Horny HP, Lennert K. Tissue mast cells in health and disease. Pathol Res Pract 1985;179:439-61.
26. Escribano L, Orfao A, Diaz-Agustin B, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998;91:2731-6.
27. Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103:3222-5.
28. Valent P, Sperr WR, Samorapoompichit P, et al. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. Leuk Res 2001;25:595-602.
29. Agis H, Beil WJ, Bankl HC, et al. Mast cell-lineage versus basophil lineage involvement in myeloproliferative and myelodysptastic syndromes: diagnostic role of cell-immunopnenotyping. Leuk Lymphoma 1996;22:187-204.
30. Prokocimer M, Polliack A. Increased bone marrow mast cells in preleukemic syndromes, acute leukemia, and lymphoproliferative disorders. Am J Clin Pathol 1981;75:34-8.
31. Jordan JH, Schernthaner GH, Fritsche-Polanz R, et al. Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to recently established SM-criteria. Leuk Lymphoma 2002;43:575-82.